Chronic Administration of Anti-Stroke Herbal Medicine TongLuoJiuNao Reduces Amyloidogenic Processing of Amyloid Precursor Protein in a Mouse Model of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  He, Ping ^a   Li, Pengtao ^b   Hua, Qian ^b   Liu, Yuan ^b   Staufenbiel, Matthias ^c   Li, Rena ^a   Shen, Yong ^a  

^a ROSKAMP INSTITUTE   (United States)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; BETA SECRETASE 1; GAMMA SECRETASE; GENIPOSIDE; GINSENOSIDE RG 1; HERBACEOUS AGENT; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; NEUROPROTECTIVE AGENT; NICASTRIN; PRESENILIN 1; PRESENILIN 2; TONGLUAOJIUNAO; UNCLASSIFIED DRUG; AMYLOID; APH1A PROTEIN, MOUSE; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; CENTRAL NERVOUS SYSTEM AGENTS; DRUG COMBINATION; GINSENOSIDE; IRIDOID; MEMBRANE PROTEIN; NICASTRIN PROTEIN; PRESENILIN ENHANCER 2, MOUSE; PROTEINASE; SECRETASE; TONGLUO JIUNAO;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; HERBAL MEDICINE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; ANIMAL; C57BL MOUSE; DRUG COMBINATION; HUMAN; METABOLISM; MUTATION; STROKE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CENTRAL NERVOUS SYSTEM AGENTS; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; ENDOPEPTIDASES; GINSENOSIDES; HUMANS; IRIDOIDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; STROKE;

EID: 84874614212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058181     Document Type: Article

References (72)

1. Liu Y, Hua Q, Lei H, Li P, (2011) Effect of Tong Luo Jiu Nao on Abeta-degrading enzymes in AD rat brains. J Ethnopharmacol 137: 1035-1046.
2. Li XJ, Hou JC, Sun P, Li PT, He RQ, et al. (2012) Neuroprotective effects of tongluojiunao in neurons exposed to oxygen and glucose deprivation. J Ethnopharmacol 141: 927-933.
3. Gu Z, Zhao J (2007) Clinical Trials of TongLuoJiuNao in Patients with Acute Brain Infarcts. Changchun Medical School of Chinese Medicine Bulletin.
4. Zhu W, Xiong J, (2007) Clinical studies of TongLuoJiuNao in patients with acute infarcts. Hubei Med School of Chinese Medicine Bulletin 5: 4-39.
5. Kim BH, Lee YG, Park TY, Kim HB, Rhee MH, et al. (2009) Ginsenoside Rp1, a ginsenoside derivative, blocks lipopolysaccharide-induced interleukin-1beta production via suppression of the NF-kappaB pathway. Planta Med 75: 321-326.
6. Joo SS, Yoo YM, Ahn BW, Nam SY, Kim YB, et al. (2008) Prevention of inflammation-mediated neurotoxicity by Rg3 and its role in microglial activation. Biol Pharm Bull 31: 1392-1396.
7. Kim YJ, Kwon HC, Ko H, Park JH, Kim HY, et al. (2008) Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biol Pharm Bull 31: 826-830.
8. Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, et al. (2009) Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 73: 811-816.
9. Zhang X, Wang J, Xing Y, Gong L, Li H, et al. (2012) Effects of ginsenoside Rg1 or 17beta-estradiol on a cognitively impaired, ovariectomized rat model of Alzheimer's disease. Neuroscience 220: 191-200.
10. Shi C, Zheng DD, Fang L, Wu F, Kwong WH, et al. (2012) Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim Biophys Acta 1820: 453-460.
11. Yin F, Liu J, Zheng X, Guo L, Xiao H, (2010) Geniposide induces the expression of heme oxygenase-1 via PI3K/Nrf2-signaling to enhance the antioxidant capacity in primary hippocampal neurons. Biol Pharm Bull 33: 1841-1846.
12. Liu JH, Yin F, Guo LX, Deng XH, Hu YH, (2009) Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 30: 159-165.
13. Bertram L, Tanzi RE, (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9: 768-778.
14. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
15. Selkoe DJ, (2003) Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res 28: 1705-1713.
16. Tanzi RE, Bertram L, (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555.
17. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC, (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
18. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G, (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786.
19. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101: 3632-3637.
20. Yang LB, Lindholm K, Yan R, Citron M, Xia W, et al. (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4.
21. Ji HF, Zhang HY, (2008) Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin 29: 143-151.
22. Williams P, Sorribas A, Howes MJ, (2011) Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 28: 48-77.
23. Bao HY, Zhang J, Yeo SJ, Myung CS, Kim HM, et al. (2005) Memory enhancing and neuroprotective effects of selected ginsenosides. Arch Pharm Res 28: 335-342.
24. Liu Y, Li X, Yuan HF, (2006) [Progress of research on effects of ginsenoside Rg1 in promoting capability of learning and memory]. Zhongguo Zhong Xi Yi Jie He Za Zhi 26: 956-960.
25. Chang Y, Huang WJ, Tien LT, Wang SJ, (2008) Ginsenosides Rg1 and Rb1 enhance glutamate release through activation of protein kinase A in rat cerebrocortical nerve terminals (synaptosomes). Eur J Pharmacol 578: 28-36.
26. Chen F, Eckman EA, Eckman CB, (2006) Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J 20: 1269-1271.
27. Zhao H, Li Q, Zhang Z, Pei X, Wang J, et al. (2009) Long-term ginsenoside consumption prevents memory loss in aged SAMP8 mice by decreasing oxidative stress and up-regulating the plasticity-related proteins in hippocampus. Brain Res 1256: 111-122.
28. Wang YH, Du GH, (2009) Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res 11: 604-612.
29. Chen LM, Lin ZY, Zhu YG, Lin N, Zhang J, et al. (2012) Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells. Eur J Pharmacol 675: 15-21.
30. He P, Cheng X, Staufenbiel M, Li R, Shen Y (2013) Long-term Treatment of Thalidomide Ameliorates Amyloid-like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer's Disease. PLoS One: Epub Feb 06.
31. Hua Q, Qing X, Li P, Li W, Hou J, et al. (2010) Brain microvascular endothelial cells mediate neuroprotective effects on ischemia/reperfusion neurons. J Ethnopharmacol 129: 306-313.
32. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292.
33. Sommer B, Staufenbiel M (1998) A beta peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis. Mol Psychiatry 3: 284-286, 282-283.
34. He P, Zhong Z, Lindholm K, Berning L, Lee W, et al. (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178: 829-841.
35. He P, Shen Y, (2009) Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease. J Neurosci 29: 6545-6557.
36. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, et al. (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7: 609-618.
37. He P, Liu Q, Wu J, Shen Y, (2012) Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J 26: 334-345.
38. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
39. LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309: 274-284.
40. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
41. Van Dooren T, Muyllaert D, Borghgraef P, Cresens A, Devijver H, et al. (2006) Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol 168: 245-260.
42. Gandy S, (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115: 1121-1129.
43. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537-540.
44. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, et al. (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419-427.
45. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533-537.
46. Lin X, Koelsch G, Wu S, Downs D, Dashti A, et al. (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 97: 1456-1460.
47. Selkoe DJ, (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17: 1060-1065.
48. Selkoe D, Kopan R, (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26: 565-597.
49. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100: 4162-4167.
50. Yin F, Zhang Y, Guo L, Kong S, Liu J (2012) Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Abeta1-42 in cortical neurons. CNS Neurol Disord Drug Targets.
51. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, et al. (2010) Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 19: 977-989.
52. Cole SL, Vassar R, (2008) The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283: 29621-29625.
53. Zhang C, Browne A, Divito JR, Stevenson JA, Romano D, et al. (2010) Amyloid-beta production via cleavage of amyloid-beta protein precursor is modulated by cell density. J Alzheimers Dis 22: 683-984.
54. Velliquette RA, O'Connor T, Vassar R, (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25: 10874-10883.
55. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, et al. (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60: 988-1009.
56. Vassar R, (2007) Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease. Neuron 54: 671-673.
57. Choi K, Kim M, Ryu J, Choi C, (2007) Ginsenosides compound K and Rh(2) inhibit tumor necrosis factor-alpha-induced activation of the NF-kappaB and JNK pathways in human astroglial cells. Neurosci Lett 421: 37-41.
58. Choo MK, Sakurai H, Kim DH, Saiki I, (2008) A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. Oncol Rep 19: 595-600.
59. Zhang Z, Li X, Lv W, Yang Y, Gao H, et al. (2008) Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol 22: 186-195.
60. Best JD, Jay MT, Otu F, Ma J, Nadin A, et al. (2005) Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-d ihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 313: 902-908.
61. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, et al. (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30: 317-325.
62. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66: 602-604.
63. Schroeter EH, Kisslinger JA, Kopan R, (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 382-386.
64. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, et al. (2002) Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277: 6318-6323.
65. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, et al. (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278: 46107-46116.
66. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876-12882.
67. Kraft AD, Johnson DA, Johnson JA, (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24: 1101-1112.
68. Yin F, Liu JH, Zheng XX, Guo LX, (2010) GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin 31: 540-545.
69. Jazwa A, Cuadrado A, (2010) Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr Drug Targets 11: 1517-1531.
70. Guo LX, Xia ZN, Gao X, Yin F, Liu JH, (2012) Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cells. Acta Pharmacol Sin 33: 237-241.
71. Duarte AI, Santos MS, Oliveira CR, Rego AC, (2005) Insulin neuroprotection against oxidative stress in cortical neurons-involvement of uric acid and glutathione antioxidant defenses. Free Radic Biol Med 39: 876-889.
72. Hua Q, Zhu X, Li P, Tang H, Cai D, et al. (2008) Refined Qing Kai Ling, traditional Chinese medicinal preparation, reduces ischemic stroke-induced infarct size and neurological deficits and increases expression of endothelial nitric oxide synthase. Biol Pharm Bull 31: 633-637.